RecruitingNCT07268833

Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy


Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Enrollment

400 participants

Start Date

Oct 24, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The progress of ALS research and clinical practice is hampered by lack of effective biomarkers to monitor disease onset and progression. In response to this urgent need, we will integrate single-cell system biology approaches, histopathological and clinical data from precious human nerve biopsies collected from living ALS patients during the diagnostic workup and findings from innovative preclinical mouse models to unmask cell-specific molecular alterations that arise in the PNS tissue during the course of ALS pathology. This information will be used to select protein biomarkers of dysfunctional states associated with pre-manifest or early symptomatic stages of the disease, which will be further screened and validated in patient biofluids. Altogether, this project will lead to the discovery of novel, reliable and specific ALS biomarkers while providing insights into ALS mechanisms by leveraging an original "PNS perspective" on disease pathogenesis.


Eligibility

Min Age: 18 Years

Inclusion Criteria11

  • Age equal or over 18 years old
  • ALS patients, diagnosed accordingly to the revised El Escorial Criteria
  • Disease duration <24 months from symptom onset.
  • Age equal or over 18 years old
  • Age equal or over 18 years old
  • Subjects without a diagnosis of neurodegenerative disease or neuromuscular disorder.
  • Age equal or over 18 years old
  • For AD: Diagnosis according to 2018 NIA-AA Framework for Alzheimer's Disease
  • For FTD: Diagnosis according to 2011 International Behavioural Variant FTD Criteria Consortium
  • For PD: Diagnosis according to 2015 Movement Disorder Society criteria
  • Age equal or over 18 years old

Exclusion Criteria7

  • FVC <60%;
  • nutritional or respiratory failure;
  • significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
  • significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
  • significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
  • significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
  • significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

Azienda Ospedaliero Universitaria di Cagliari

Monserrato, California, Italy

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy

IRCCS Ospedale San Raffaele SRL

Milan, Italy

Azienda Ospedaliera Universitaria Federico II

Naples, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07268833


Related Trials